colistimethate sodium has been researched along with Cystic Fibrosis in 30 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (13.33) | 29.6817 |
2010's | 22 (73.33) | 24.3611 |
2020's | 4 (13.33) | 2.80 |
Authors | Studies |
---|---|
Blau, H; Kadosh, D; Kalamaro, V; Landau, E; Mantin, H; Mei-Zahav, M; Mussaffi, H; Prais, D; Quittner, A; Taizi, T | 1 |
Crass, RL; Fitzgerald, LJ; Han, MK; Jia, S; Lenhan, BE; Lipp, MA; Patel, TS; Simon, RH | 1 |
Bilton, D; Caine, N; Charman, SC; Kaplan, S; Lee, A | 1 |
Bradbury, P; Kassiou, M; Ong, HX; Pozzoli, M; Reekie, TA; Robinson, PD; Sheikh, Z; Traini, D; Young, PM | 1 |
Cao, W; Debonnett, L; Greenwood, J; Hamed, K; Mastoridis, P; Nash, EF; Schwarz, C; Sommerwerck, U; Tamm, M | 1 |
Arenzana Seisdedos, Á; Cantón-Bulnes, ML; Garnacho-Montero, J; Hurtado Martínez, Á; López-Cerero, L; Merino-Bohorquez, V | 1 |
Cogen, JD; Goss, CH; Nichols, DP; Nick, JA; Nick, SE; Russell, R; Saavedra, MT; Somayaji, R; Taylor-Cousar, JL | 1 |
Altay, A; Buttini, F; Colombo, G; Kozáková, J; Mašková, L; Quarta, E; Rossi, A; Sonvico, F; Ždímal, V | 1 |
Aanaes, K; Alanin, M; Hjuler, T; Johansen, HK; Skov, M; von Buchwald, C | 1 |
Cantrell, A; Carroll, C; Harnan, S; Mildred, M; Tappenden, P; Uttley, L | 1 |
Brownlee, K; Cantrell, A; Harnan, S; Tappenden, P; Taylor, C; Uttley, L; Walshaw, M | 1 |
Brownlee, K; Harnan, S; Mildred, M; Tappenden, P; Taylor, C; Uttley, L; Walshaw, M | 1 |
Clark, P; Knight, H; Nolan, K | 1 |
Conole, D; Keating, GM | 1 |
Clark, D; Dooley, MJ; George, J; Li, J; McIntosh, MP; Nation, RL; Patel, K; Poole, S; Porter, CJ; Williams, E; Wilson, JW; Yapa, SWS | 1 |
Fiel, SB | 1 |
Tappenden, P; Uttley, L | 1 |
Asensio, VJ; Bachiller, D; Esquisabel, A; Gainza, E; Moreno-Sastre, M; Pastor, M; Pedraz, JL; Pozo, AD; Sans, E; Viñas, M | 1 |
Dasenbrook, EC; Konstan, MW; VanDevanter, DR | 1 |
Balducci, AG; Buttini, F; Colombo, G; Di Cuia, M; Elviri, L; Rossi, A; Rossi, I; Sonvico, F | 1 |
Bachiller, D; Esquisabel, A; Moreno-Sastre, M; Pastor, M; Pedraz, JL; Sans, E; Viñas, M | 1 |
Cho, E; Davidson, AG; Lillquist, YP | 1 |
Angyalosi, G; Balp, MM; Capkun-Niggli, G; Doering, G; Higashi, K; Jansen, JP; Littlewood, KJ; Tiddens, HA | 1 |
Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT | 1 |
Döring, G; Goldman, MH; Haliburn, C; Schuster, A | 1 |
Calero, C; Dapena, FJ; Lopez-Campos, JL; Quintana-Gallego, E | 1 |
Conway, S; Coulthard, K; Etherington, C; Li, J; Milne, R; Nation, RL; Peckham, D; Turnidge, J | 1 |
Li, J | 1 |
McCoy, KS | 1 |
Coulthard, K; Li, J; Milne, R; Nation, RL; Turnidge, J | 1 |
7 review(s) available for colistimethate sodium and Cystic Fibrosis
Article | Year |
---|---|
Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.
Topics: Administration, Inhalation; Child; Colistin; Cost-Benefit Analysis; Cystic Fibrosis; Disease Progression; Humans; Outcome Assessment, Health Care; Pseudomonas aeruginosa; Pseudomonas Infections; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Therapeutic Equivalency; Tobramycin; United Kingdom | 2013 |
Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Disease Progression; Dry Powder Inhalers; Evidence-Based Medicine; Forced Expiratory Volume; Humans; Lung; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Research Design; Time Factors; Tobramycin; Treatment Outcome | 2013 |
Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Topics: Chronic Disease; Colistin; Cystic Fibrosis; Drug Resistance, Bacterial; Dry Powder Inhalers; Humans; Lung; Pseudomonas aeruginosa; Pseudomonas Infections | 2014 |
Aerosolized antibiotics in cystic fibrosis: an update.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Aztreonam; Colistin; Cystic Fibrosis; Equipment Design; Humans; Levofloxacin; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin | 2014 |
Dry powder inhalers in cystic fibrosis: same old drugs but different benefits?
Topics: Administration, Inhalation; Anti-Bacterial Agents; Colistin; Cost-Benefit Analysis; Cystic Fibrosis; Dry Powder Inhalers; Humans; Medication Adherence; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2014 |
A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Aztreonam; Bacterial Load; Bayes Theorem; Biological Availability; Chronic Disease; Colistin; Cystic Fibrosis; Disease Progression; Female; Forced Expiratory Volume; Humans; Information Services; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Tobramycin; Treatment Outcome | 2012 |
Difficulty in assaying colistin methanesulphonate.
Topics: Animals; Colistin; Cystic Fibrosis; Humans | 2005 |
4 trial(s) available for colistimethate sodium and Cystic Fibrosis
Article | Year |
---|---|
Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Colistin; Cross-Over Studies; Cystic Fibrosis; Equipment Contamination; Equipment Design; Europe; Female; Forced Expiratory Volume; Humans; Lung; Male; Nebulizers and Vaporizers; Patient Satisfaction; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Time Factors; Tobramycin; Treatment Outcome; Young Adult | 2017 |
Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Female; Humans; Lung; Male; Middle Aged; Sputum | 2014 |
Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Colistin; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Male; Powders; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome; Young Adult | 2013 |
[Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients].
Topics: Administration, Inhalation; Body Mass Index; Child; Child, Preschool; Colistin; Cross-Over Studies; Cystic Fibrosis; Drug Resistance, Bacterial; Female; Forced Expiratory Volume; Humans; Lung; Male; Nebulizers and Vaporizers; Patient Satisfaction; Pseudomonas aeruginosa; Sputum; Surveys and Questionnaires; Tobramycin; Treatment Outcome | 2014 |
19 other study(ies) available for colistimethate sodium and Cystic Fibrosis
Article | Year |
---|---|
Efficacy of Problem-Solving Intervention to Improve Adherence in Adolescents and Adults with Cystic Fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Body Mass Index; Colistin; Cystic Fibrosis; Female; Forced Expiratory Volume; Humans; Male; Medication Adherence; Patient-Centered Care; Problem Solving; Quality of Life; Tobramycin; Young Adult | 2021 |
Acute kidney injury in cystic fibrosis patients treated with intravenous colistimethate sodium or tobramycin.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Tobramycin; Vancomycin | 2022 |
Long-term safety study of colistimethate sodium (Colobreathe®): Findings from the UK Cystic Fibrosis Registry.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Colistin; Cystic Fibrosis; Female; Humans; Male; Middle Aged; Pseudomonas Infections; Registries; Respiratory Tract Infections; Symptom Flare Up; United Kingdom | 2021 |
Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cell Survival; Colistin; Cystic Fibrosis; Drug Combinations; Humans; Ibuprofen; Inflammation; Interleukin-8; Lipopolysaccharides; Pseudomonas aeruginosa; Tobramycin | 2021 |
A case of pan-resistant Burkholderia cepacia complex bacteremic pneumonia, after lung transplantation treated with a targeted combination therapy.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Burkholderia cepacia complex; Burkholderia Infections; Colistin; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Humans; Lung Transplantation; Male; Pneumonia, Bacterial; Treatment Outcome; X-Rays | 2019 |
Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.
Topics: Administration, Inhalation; Administration, Intravenous; Adult; Anti-Bacterial Agents; Azithromycin; Colistin; Cystic Fibrosis; Disease Progression; Female; Forced Expiratory Volume; Humans; Logistic Models; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin; Young Adult | 2019 |
Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction.
Topics: Administration, Inhalation; Aerosols; Colistin; Cystic Fibrosis; Drug Compounding; Dry Powder Inhalers; Humans; Infections; Lung; Particle Size; Powders; Solvents | 2019 |
The effect of sinus surgery with intensive follow-up on pathogenic sinus bacteria in patients with cystic fibrosis.
Topics: Achromobacter denitrificans; Adolescent; Adult; Burkholderia; Burkholderia Infections; Child; Chronic Disease; Colistin; Cystic Fibrosis; Female; Follow-Up Studies; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged; Nasal Lavage; Paranasal Sinuses; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Rhinitis; Sinusitis; Treatment Outcome; Young Adult | 2013 |
The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Colistin; Cost-Benefit Analysis; Cystic Fibrosis; Decision Support Techniques; Dry Powder Inhalers; Humans; Models, Economic; Pneumonia, Bacterial; Probability; Pseudomonas aeruginosa; Pseudomonas Infections; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Tobramycin; Young Adult | 2014 |
NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Clinical Trials as Topic; Colistin; Cystic Fibrosis; Drug Monitoring; Drug Therapy, Combination; Dry Powder Inhalers; Humans; Practice Guidelines as Topic; Pseudomonas Infections; Respiratory Function Tests; Respiratory Tract Infections; State Medicine; Tobramycin; United Kingdom | 2013 |
Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Cell Line; Cell Survival; Colistin; Cystic Fibrosis; Drug Carriers; Drug Delivery Systems; Drug Liberation; Humans; Lipids; Mice; Microbial Sensitivity Tests; Nanoparticles; Particle Size; Pseudomonas aeruginosa; Pseudomonas Infections; Surface Properties; Tissue Distribution | 2014 |
Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.
Topics: Administration, Inhalation; Adolescent; Adult; Aerosols; Anti-Bacterial Agents; Aztreonam; Child; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Tobramycin; Treatment Outcome; Young Adult | 2015 |
Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Bacterial Infections; Colistin; Cystic Fibrosis; Humans; Lung Diseases; Nebulizers and Vaporizers; Solutions | 2016 |
Stability study of sodium colistimethate-loaded lipid nanoparticles.
Topics: Colistin; Cystic Fibrosis; Drug Stability; Humans; Lipids; Nanoparticles; Pseudomonas aeruginosa; Pseudomonas Infections | 2016 |
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Burkholderia cepacia complex; Child; Child, Preschool; Ciprofloxacin; Cohort Studies; Colistin; Cystic Fibrosis; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Health Care Costs; Health Resources; Humans; Infant; Injections, Intravenous; Nebulizers and Vaporizers; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2011 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Disease Progression; Female; Humans; Male; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Young Adult | 2013 |
Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Colistin; Cystic Fibrosis; Drug Stability; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged | 2003 |
Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Drug Compounding; Fatal Outcome; Female; Humans; Nebulizers and Vaporizers; Prodrugs; Pseudomonas Infections; Respiratory Distress Syndrome | 2007 |
In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Humans; Kinetics; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2001 |